World Journal of
Experimental Medicine

World Journal of Experimental Medicine

Contents

Contents

LETTER TO THE EDITOR

Contents

ABOUT COVER

Peer Reviewer of *World Journal of Experimental Medicine*, Wu Duan, MD, PhD, Assistant Professor, Attending Doctor, Department of Endocrinology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China. duanwu@qiluhospital.com

AIMS AND SCOPE

The primary aim of the *World Journal of Experimental Medicine* (*WJEM*, *World J Exp Med*) is to provide scholars and readers from various fields of experimental medicine with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

    WJEM mainly publishes articles reporting research results and findings obtained in the field of experimental medicine and covering a wide range of topics including clinical laboratory medicine (applied and basic research in hematology, body fluid examination, cytomorphology, genetic diagnosis of hematological disorders, thrombosis and hemostasis, and blood typing and transfusion), biochemical examination (applied and basic research in laboratory automation and information system, biochemical methodology, and biochemical diagnostics), *etc*.

INDEXING/ABSTRACTING

The *WJEM* is now abstracted and indexed in PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The *WJEM*'s CiteScore for 2023 is 1.7 and Scopus CiteScore rank 2023: Internal medicine is 109/167.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Lei Zhang*; **Production Department Director:** *Xu Guo*; **Cover Editor:** *Ji-Hong Liu*.

Observational Study

Haematology results, inflammatory haematological ratios, and inflammatory indices in cervical cancer: How is the difference between cancer stage?

Phey Liana, Hanif Gusneri Syahbiran, Nurmalia Purnama Sari, Kemas Yakub Rahadiyanto, Raissa Nurwany, Wahyudi Nurhidayat, Tungki Pratama Umar

Phey Liana, Nurmalia Purnama Sari, Department of Clinical Pathology, Faculty of Medicine, Universitas Sriwijaya-Dr. Mohammad Hoesin General Hospital, Palembang 30114, Sumatera Selatan, Indonesia

Hanif Gusneri Syahbiran, Department of Medicine Programme, Faculty of Medicine, Universitas Sriwijaya, Palembang 30114, Sumatera Selatan, Indonesia

Kemas Yakub Rahadiyanto, Department of Clinical Pathology, Faculty of Medicine, Universitas Sriwijaya, Palembang 30114, Sumatera Selatan, Indonesia

Raissa Nurwany, Department of Physiology and Medical Physics, Faculty of Medicine, Universitas Sriwijaya, Palembang 30114, Sumatera Selatan, Indonesia

Wahyudi Nurhidayat, Department of Radiotherapy, Dr. Mohammad Hoesin General Hospital, Palembang 30114, Sumatera Selatan, Indonesia

Tungki Pratama Umar, Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London WC1E 6BT, United Kingdom

Corresponding author: Phey Liana, MBBS, MD, PhD, Associate Professor, Lecturer, Researcher, Department of Clinical Pathology, Faculty of Medicine, Universitas Sriwijaya-Dr. Mohammad Hoesin General Hospital, Dr. Mohammad Ali Street, RSMH Complex Palembang, Indonesia, Palembang 30114, Sumatera Selatan, Indonesia. pheyliana@fk.unsri.ac.id

Abstract

BACKGROUND

Cervical cancer is a prevalent form of cancer affecting women worldwide and it is the second most common cancer among women in Indonesia, accounting for 8.5% of all cancer-related deaths. Cervical cancer progression can be evaluated through laboratory tests to detect anaemia, an increased platelet count, and elevated inflammatory markers, therefore, effective laboratory examination is crucial for early detection and treatment of cervical cancer.

AIM

To evaluate the association between laboratory findings (haematology, haemato-

logy index, and inflammatory index) and the clinical stage of cervical cancer.

METHODS
This cross-sectional study analyzed adult cervical cancer patients' data from medical records and laboratory results including sociodemographic status, histopathological finding, clinical stage, and complete haematology examination. Numerical data was analyzed by the one-way ANOVA (normal data distribution), while the Kruskal-Wallis test was used for non-parametric data (abnormal distribution), followed by appropriate post-hoc analysis. The categorical data was analyzed by the Chi-square or Fisher Exact tests. The significance level was established at a P value < 0.05.

RESULTS
This study involved the data of 208 adult cervical cancer patients and found no association between age, marital history, parity history, hormonal contraceptive use and cervical cancer stages. There were significant differences in the clinical laboratory test results based on the clinical stage of cervical cancer, including haemoglobin levels ($P < 0.001$), leucocytes ($P < 0.001$), neutrophils ($P < 0.001$), monocytes ($P = 0.002$), lymphocytes ($P = 0.006$), platelets ($P < 0.001$), neutrophil-lymphocyte ratio/NLR ($P < 0.001$), lymphocyte-monocyte ratio/LMR ($P < 0.001$), and platelet-lymphocyte ratio/PLR ($P < 0.001$). There were also significant differences in the systemic inflammatory index (SII) and systematic inflammatory response index (SIRI) between stage III + IV cervical cancer and stage II (SII $P < 0.001$; SIRI $P = 0.001$) and stage I (SII $P < 0.001$; SIRI $P = 0.016$), associated with the shifts in previously mentioned complete haematological values with cancer advancement.

CONCLUSION
The haematological parameters, inflammatory haematological ratios, and inflammatory indices exhibited significant differences between cervical cancer stages, therefore these tests can be utilized to evaluate cervical cancer progression.

Key Words: Cervical cancer; Haematology; Haematology index; Inflammation; Malignancy

Core Tip: The current investigation of 208 adult cervical patients found that hematologic parameters such as leucocyte, neutrophil, monocyte, and platelet counts vary significantly depending on the cervical cancer clinical stage. There were significant changes in inflammatory haematological ratios (neutrophil-lymphocyte ratio/NLR, platelet-lymphocyte ratio/PLR, and lymphocyte-monocyte ratio/LMR) and inflammatory indices (systemic immune-inflammation index/SII and systemic inflammation response index/SIRI), particularly between patients with stage III + IV and those with stage II and I cervical cancer. The analysis revealed that the cervical cancer clinical stage is highly related to the hematologic parameters.

INTRODUCTION

Cervical cancer is characterized by the uncontrolled growth of aberrant cells in the cervix uteri[1]. This cancer is the fourth most prevalent form of cancer affecting women worldwide[2] and is the second most prevalent cancer in Indonesian women with 36964 new cervical cancer cases and 20708 fatalities accounting for 8.5% of all cancer-related deaths[3]. Sexual contact is the primary factor contributing to disease transmission by exposure to the human papillomavirus (HPV). HPV is the primary oncogenic virus in women, responsible for around 90% of cervical cancer cases when there is a persistent high-risk HPV infection including HPV type 16 and 18[4].

Cervical cancer is frequently diagnosed at an advanced stage due to the lack of detection methods but is one of the most treatable forms of cancer if identified within the pre-cancerous stage[5]. A meta-analysis of 53,233 participants demonstrated that the incidence of late-stage cervical cancer patient presentation accounted for 60.66% of all cases worldwide, with Africa (62.60%) and Asia (69.30%) having higher rates than the global average[6]. This is primarily due to the individual's educational attainment, economic circumstance, geographical location, and pre-referral diagnosis by primary healthcare professionals[6,7]. This would undoubtedly exacerbate the death rate of cervical cancer, particularly in low-income nations, therefore, early identification is crucial in this case.

Various laboratory tests can be used to evaluate cervical cancer progression[8]. For instance, advanced cancer can cause chronic anaemia due to excessive cytokines directly and indirectly suppressing erythropoiesis[9]. Tumours also release cytokines that stimulate the formation of megakaryocytes and thrombopoiesis, resulting in an elevated platelet count[10]. Chronic inflammation also promotes the advancement of tumours and makes them more resistant to treatment. Therefore, cancer progression is linked to various inflammatory pathways, such as nuclear factor kappa B, Janus kinase/ signal transducers and activators of transcription, toll-like receptor, and several proinflammatory cytokines [*e.g.*, interleukin (IL), interferon, and tumour necrosis factor][11]. Thus, there may be alterations in the leucocyte count and the com-position of leucocytes including neutrophils, lymphocytes, and monocytes[12]. For example, there is a correlation bet -ween the neutrophil-lymphocyte ratio (NLR) and cancer severity with the NLR tending to increase as the cancer progresses[13]. NLR is linked to increased cytokines [IL-1, IL-6, IL-7, IL-8, IL-12, IL-17, granulocyte colony-stimulating factor (G-CSF), and monocyte chemoattractant protein-1] that boost the activity of tumour macrophages[14]. Furthermore, reduced lymphocytes during advanced cancer may impact immune surveillance, causing diminished CD4+ T cells and an altered CD4+/CD8+ ratio related to rapid tumour growth and lymph node infiltration which are associated with platelet-lymphocyte ratio (PLR) elevation[15]. Moreover, there is evidence of elevated levels of inflammatory markers, such as the systemic inflammation index (SII) and systemic inflammatory response index (SIRI) in some cancers, including lung, pancreatic, and breast cancers[16-18]. However, SIRI prognostic significance has not been widely examined in cervical cancer, although nomogram creation utilizing SIRI, International Federation of Gynecology and Obstetrics (FIGO) stage, and lymphovascular invasion could better predict cervical cancer prognosis than FIGO stage alone because it may indicate the dynamic tumour burden and immune response status in patients[19].

Therefore, this study aimed to evaluate the association between laboratory findings (haematology, inflammatory haematological ratios, and inflammatory indices) and the clinical stage of cervical cancer to facilitate early diagnosis of cervical cancer and ultimately enhance the prognosis of people living with cancer by utilizing readily available biomarkers.

MATERIALS AND METHODS

This cross-sectional study collected data of cervical cancer patients from the Medical Records and Central Laboratory Installation of Dr Mohammad Hoesin General Hospital in Palembang, Indonesia (a tertiary-level facility). Cervical cancer patients aged ≥ 18 years and diagnosed from August 2022 to July 2023 were recruited using the total sampling technique considering a minimum sample size of 207, with an enrolment ratio of two, $\alpha = 0.05$, and $\beta = 80\%$. The study was approved by the medical and health research ethics committee of the Faculty of Medicine, Universitas Sriwijaya (Protocol No. 301-2023).

The data included information on the patient's sociodemographic status (such as age, marital status, parity, and hormonal contraceptive use), histopathological examinations, clinical stage of cervical cancer, and a comprehensive haematological examination (haemoglobin, leucocyte, neutrophil, monocyte, lymphocyte, and platelet counts). Additionally, haematological indices such as the NLR, PLR, and lymphocyte-monocyte ratio (LMR), as well as inflammatory indices, namely the SIRI and SII were also recorded[20].

The clinical stages of cervical cancer were classified according to the FIGO 2018 staging classification of cervical cancer, categorizing the disease into four main stages: I, II, III, and IV[21]. The participants were categorized into three distinct stages: Stage I, stage II, and stage III + IV due to the limited number of samples available in Stage IV. The NLR was determined by dividing the number of neutrophils by the number of lymphocytes, while the PLR was calculated by dividing the numbers of platelets and lymphocytes. LMR was established by dividing the number of lymphocytes by the number of monocytes. SIRI was determined by multiplying the monocyte count by the neutrophil count and dividing it by the lymphocyte count. Meanwhile, the SII was obtained by multiplying the platelet count by the neutrophil count and then dividing it by the lymphocyte count. The haematological analysis was conducted using a Sysmex XN-1000 machine.

The statistical analysis was conducted using IBM SPSS software version 26.0 (Armonk, NY: IBM Corp), with a significance level set at P value < 0.05. The data normality was assessed using the Kolmogorov-Smirnov test on a sample size of more than 50 participants. A univariate analysis was conducted to examine the frequency distribution of each variable. Normally distributed data was analyzed by one-way analysis of variance (ANOVA) and the Kruskal-Wallis test was applied to non-normally distributed data, followed by the appropriate post hoc test, either Tukey (homogenous sample), Games-Howell (non-homogenous sample) or Bonferroni correction test (non-parametric data). The χ^2 or Fisher Exact tests were employed for categorical data.

RESULTS

This analysis involved 208 cervical cancer patients with an average age of 48.5 years who were categorized into three groups: Stage I ($n = 25$), stage II ($n = 51$), and stage III + IV ($n = 132$). Most patients (98.5%) were married with multiparity and grand multiparity as the most common parity status and five patients had a prior record of hormonal contraception. Based on histopathological analysis, the most common type of cervical cancer was squamous cell carcinoma (68.6%), followed by adenocarcinoma, mixed types, and other types. There is no statistically significant association between age and the clinical stage of cervical cancer. Furthermore, there is no statistically significant association between marital status ($P = 0.41$), parity history ($P = 0.34$), and history of hormonal contraceptive usage ($P = 0.39$) and the clinical stage of cervical cancer. Similar findings apply to parity history, hormonal contraception use, and histological classification.

The hematologic results presented in Table 1 showed that several haematologic markers including haemoglobin (P < 0.001), leucocyte counts (P < 0.001) and platelet counts (P < 0.001) exhibited statistically significant variations depending on the clinical stage. Leucocyte counts, including neutrophils (P < 0.001), monocytes (P = 0.002), and lymphocytes (P = 0.006) exhibited comparable results. The progressive increase in leucocytes, platelets, neutrophils, and monocytes illustrated the association between cervical cancer stage and haematologic results. Concurrently, haemoglobin levels exhibited a progressive decline with the increasing severity of cancer stages and varied significantly between each stage (P < 0.001). The leucocyte counts were significantly different between stage III + IV and stage II (P = 0.042) and stage I (P < 0.001). Neutrophils exhibited a notable disparity between stage III + IV and stage II (P = 0.006) as well as stage I (P < 0.001). However, only significant differences between stage III + IV and stage II were observed for monocytes (P = 0.002) and lymphocytes (P = 0.005).

Furthermore, analysis of the haematological indices NLR (P < 0.001), PLR (P < 0.001), and LMR (P < 0.001) revealed notable variations depending on the clinical stage. The NLR and PLR results were comparable, with notable differences in the levels of these indicators between patients with stage III + IV and stage II (NLR P < 0.001; PLR P = 0.001) and stage I (NLR P < 0.001; PLR P < 0.001). However, LMR was only different between stage I and stage II (P = 0.004) and stage III + IV (P = 0.019), suggesting that monocytes are not significantly elevated between these clinical stages. These changes are attributed to lower lymphocyte counts and elevated neutrophil and platelet counts along with disease progression.

There were significant differences in all inflammatory indexes based on the severity of cervical cancer (P < 0.001). Post-hoc analysis revealed significant differences in SII values between patients with stage III + IV and those with stage II (P < 0.001) and stage I (P < 0.001). Similarly, the SIRI was significantly different between stage III + IV and stage II (P = 0.001) and stage I (P = 0.016), demonstrating increased inflammation in patients with a more advanced cancer stage.

DISCUSSION

The present investigation evaluated the association between laboratory findings (haematology, haematology index, and inflammatory index) and the clinical stage of cervical cancer using data from 208 patients with an average age of 48.5 ± 10.25 years which is consistent with the global average age of cervical cancer diagnosis (53 years, range: 45 to 68 years) [22]. Moreover, the lack of an association between parity history and hormonal contraceptive use with cancer stage is consistent with findings from several earlier studies[23-26].

There were significant differences in the laboratory findings among the various stages of cervical cancer. The haemoglobin levels decreased with cancer progression in line with the study of Kunos *et al*[27] which demonstrated a significant association (P = 0.01) between pre-therapy haemoglobin levels and the cervical cancer stage[27]. Another investigation conducted in Tianjin, China also demonstrated a notable association between the presence of anaemia and the cervical cancer stage (P = 0.002)[28]. The causes of anaemia in cervical cancer are multifaceted. It can arise from a haemorrhage associated with the vulnerability of the newly formed blood vessels or from cytokine activation which inhibits the generation of erythropoietin, hindering the body's ability to use iron and decreasing the formation of erythroid precursors[9,29,30].

Non-haematopoietic cancers, including cervical cancers frequently exhibit leukemoid response, characterized by leucocytosis caused by factors external to the bone marrow[31]. This study demonstrated a notable disparity in leucocyte counts among the different cancer stages with the most substantial increase observed in stages III and IV. Prior studies have also demonstrated that individuals with advanced cervical cancer exhibited more leucocyte abnormalities. Moreover, the increased neutrophil and monocyte counts, and decreased lymphocytes observed in the present study correlated with the progressive nature of cervical cancer. Previously, neutrophilia was demonstrated to be the most reliable indication of tumour cell invasiveness, which is directly linked to the malignancy severity[32]. The precise mechanism of neutrophilia within the tumour remains uncertain but it involves many cytokines including G-CSF, IL-1, and IL-6 produced by the tumour[14,33]. The present study observed a notable disparity in lymphocyte levels in advanced clinical stages (III-IV), in line with a previous study that reported an initial rise in lymphocytes during stages I and II, followed by a sharp decline at stage IV (a decrease of 22.8% compared to healthy individuals)[8]. The decreased lymphocytes are due to a decline in the immune system's capacity to combat and eradicate tumour cells, promoting its development[34]. The suppressive effect of neutrophils on lymphocytes is also an indicator of weakened immune system [35]. There was considerable variation in monocytes dependent on the cancer stage in the present study, contradictory to prior studies that found no association between monocytosis and different disease stages. Nevertheless, elevated monocytes are a negative prognostic indicator in patients with cervical cancer[36]. Monocytosis itself may be associated with several confounding factors including smoking and drinking history, as well as liver metastasis[37].

Elevation of platelet count in this study is consistent with an advanced cancer stage. Indeed, individuals with thrombocytosis were more commonly diagnosed with advanced stages (IIB-IVB) of cervical cancer[38]. Elevated platelet counts can be initiated by the secretion of cytokines including vascular endothelial growth factor and transforming growth factor-beta[39] as platelets function as a storage site that triggers the release of growth factors, which in turn stimulate the formation of new blood vessels, tumour proliferation, invasiveness, and growth[40].

As cervical cancer progresses, lymphocyte counts drop, resulting in higher NLR and PLR readings and lower LMR, as evidenced by the notable disparity in NLR[41,42] and PLR[43] across different cervical cancer clinical stages. A meta-analysis found a negative correlation between increased PLR and the prognosis of stage I and II cervical cancer patients (HR = 1.61; 95%CI: 1.21-2.15; P = 0.001) as well as stage I and IV patients (HR = 1.47; 95%CI: 1.19-1.81; P < 0.001)[43]. Prabawa *et al*[41] demonstrated a notable disparity in PLR levels (P = 0.001) between the initial and later phases of cervical cancer[41]. Elevated NLR and PLR are indicative of impaired lymphocyte function since reduced lymphocyte

Table 1 Sample characteristics, *n* (%)/mean ± SD/ median (minimum-maximum)

Variables	Total (*n* = 208)	Stage I (*n* = 25)	Stage II (*n* = 51)	Stage III + IV (*n* = 132)	*P* value
Demographics					
Age (years) (*n* = 208)	48.5 ± 10.25	44.8 ± 9.08	49.52 ± 10.80	48.80 ± 10.15	0.14[a]
> 40 tahun	41 (19.6)	18 (72.00)	40 (78.4)	109 (82.6)	0.44[c]
18-40 tahun	167 (79.9)	7 (28.00)	11 (21.60)	23 (17.4)	
Marital status (*n* = 203)					0.41[c]
Married	200 (98.5)	24 (100)	51 (100)	125 (97.7)	
Not married	3 (1.5)	0	0	3 (2.3)	
Parity history (*n* = 199)					0.34[c]
Multiparity and grand multiparity	175 (87.90)	23 (95.8)	42 (84.00)	110 (88.00)	
Nulliparity dan primiparity	24 (12.10)	1 (4.2)	8 (16.00)	15 (12.00)	
Hormonal contraception use (*n* = 173)					0.39[c]
Yes	5 (2.90)	1 (4.3)	0	4 (3.8)	
No	168 (97.10)	22 (95.7)	46 (100)	168 (97.10)	
Histolopathological classification					
Histopathological findings (*n* = 175)					0.33[c]
Squamous cell carcinoma	120 (68.60)	13 (59.10)	28 (63.60)	79 (72.5)	
Adenocarcinoma, mixed, and other	55 (31.40)	9 (40.9)	16 (36.4)	30 (27.5)	
Laboratory examinations					
Haemoglobin (g/L) (*n* = 204)	102.5 ± 24.7	124.6 ± 11.4	109.3 ± 21.2	95.4 ± 24.6	< 0.001[a]
Leucocyte (× 10^9/L) (*n* = 204)	9.85 (4.05-29.60)	7.47 (5.15-13.56)	8.84 (4.32-22.34)	11.08 (4.05-29.60)	< 0.001[b]
Neutrophil (× 10^9/L) (*n* = 186)	6.50 (1.52-25.16)	4.78 (2.66-8.90)	5.69 (3.14-17.20)	7.43 (1.52-25.16)	< 0.001[b]
Monocyte (× 10^9/L) (*n* = 186)	0.65 (0.18-2.10)	0.55 (0.33-1.22)	0.53 (0.18-1.55)	0.69 (0.27-2.10)	0.002[b]
Lymphocyte (× 10^9/L) (*n* = 186)	2.19 ± 2.15	2.18 ± 0.56	2.47 ± 0.72	2.09 ± 0.76	0.006[a]
Thrombocyte (× 10^9/L) (Neutrophil (× 10^9/L) (*n* = 186)	375.5 (99-1143)	307.00 (99.00-446.00)	364.00 (131.00-1143.00)	397.00 (147.00-791.00)	< 0.001[b]
Neutrophil lymphocyte ratio (*n* = 186)	3.13 (0.60-31.33)	2.37 (0.96-4.22)	2.31 (1.02-7.55)	3.78 (0.60-31.33)	< 0.001[b]
Lymphocyte monocyte ratio (*n* = 186)	3.29 (0.67-13.50)	3.77 ± 0.94	4.21 (1.86-13.50)	3.00 (0.67-8.25)	< 0.001[b]
Platelet lymphocyte ratio (*n* = 186)	176.01 (63.82-779.08)	141.03 (77.67-232.27)	138.96 (70.91-561.12)	200.49 (63.82-779.08)	< 0.001[b]
Systematic inflammation index (*n* = 186)	1195.47 (160.20-12282.67)	719.00 ± 309.59	1159.36 (308.71-5715.00)	1609.14 (160.20-12282.67)	< 0.001[b]
Systematic inflammatory response index (*n* = 186)	1.99 (0.25-16.54)	1.51 ± 0.80	1.17 (0.40-6.88)	2.96 (0.25-16.54)	< 0.001[b]

[a]One-Way Anova.
[b]Kruskal Wallis.
[c]χ^2 tests.

count leads to diminished immune system efficacy in combating tumour cells, facilitating tumour progression[44]. Furthermore, both NLR and PLR had a substantial capability to predict patients with tumour stages IIB and above as well as lymph node metastasis[8]. The levels of these indicators rise in patients with more advanced or aggressive illness, as seen by a growth in tumour size, nodal stage, and number of metastatic lesions[15,43,45,46]. The study demonstrated a decline in LMR during the advanced stages of cervical cancer in line with a previous study which reported a correlation between LMR and tumour stage (*P* = 0.012), as well as parametrial involvement (*P* = 0.022) and adjuvant therapy (*P* < 0.001)[47]. A low LMR is significantly correlated with specific clinicopathological parameters that are suggestive of a poor prognosis and aggressive illness[48].

In the current study, the inflammatory indicators, namely SII and SIRI, exhibited substantial differences among different clinical stages. Essentially, increased inflammatory markers were observed as a protective reaction of the body against internal or external damage, such as the development of tumours[11]. A prior investigation reported that elevated SII and SIRI are significantly linked to the likelihood of recurrence in individuals with early-stage cervical cancer. However, only a high SII relates to mortality[20]. SIRI strongly correlates with inflammatory haematological ratios, including NLR, PLR, and MLR, in matched and unmatched datasets ($P < 0.001$)[19]. Additionally, SII can differentiate the prognosis of patients in various FIGO stages, providing a valuable complement to the FIGO stage and increasing the sensitivity of screening for high-risk individuals to establish the most suitable personalised treatment[49]. Furthermore, a nomogram incorporating SIRI, FIGO stage, and lymphovascular invasion gave a better prognostic value with a c-index of 0.8, significantly higher than the FIGO stage alone ($P < 0.001$). Also, an increase in SIRI by > 75% at eight weeks after resection surgery was a risk factor for death and these patients had the worst prognosis (hazard ratio = 3.30, 95%CI: 2.08–5.25, $P < 0.001$)[19]. The inhibition of lymphocytes and T cell responses, along with elevated neutrophils, can contribute to tumour advancement, angiogenesis, and metastasis[35,50], thereby creating an inflammatory milieu. Before therapy, alterations in neutrophils and lymphocytes can indicate the extent of systemic inflammation or stress[51].

This study has several limitations including insufficient medical record data for several cervical cancer patients. The problem involves a lack of laboratory and sociodemographic data including hormonal contraceptives, which is seldom communicated in the study population. In addition, the assessment of patient outcomes, such as survival, tumour regression, or recurrence, was not conducted per this study's cross-sectional design. Furthermore, a confounding analysis was not possible due to limited data availability.

CONCLUSION

There were notable variations in the haematological parameters (haemoglobin and leucocyte, platelet, neutrophil, monocyte, and lymphocyte counts), inflammatory haematological ratios (NLR, PLR, and LMR), and inflammatory indices (SII and SIRI) across the different clinical stages of cervical cancer. Subsequent investigations should evaluate all blood-related measures and indicators, along with supplementary inflammatory markers to evaluate treatment effectiveness. Furthermore, these indicators could potentially be used to determine prognosis.

FOOTNOTES

REFERENCES

1 **Ojha PS**, Maste MM, Tubachi S, Patil VS. Human papillomavirus and cervical cancer: an insight highlighting pathogenesis and targeting strategies. *Virusdisease* 2022; **33**: 132-154 [PMID: 35991700 DOI: 10.1007/s13337-022-00768-w]

2 **Pimple S**, Mishra G. Cancer cervix: Epidemiology and disease burden. *Cytojournal* 2022; **19**: 21 [PMID: 35510109 DOI: 10.25259/CMAS_03_02_2021]

3 **Tjokroprawiro BA**, Novitasari K, Saraswati W, Yuliati I, Ulhaq RA, Sulistya HA. The challenging journey of cervical cancer diagnosis and treatment at the second largest hospital in Indonesia. *Gynecol Oncol Rep* 2024; **51**: 101325 [PMID: 38314320 DOI: 10.1016/j.gore.2024.101325]

4 **Umar TP**. Overview of oncogenic virus and its role on cancer development. *Southeast Asian J Health Prof* 2022; **5**: 56-57 [DOI: 10.18231/j.sajhp.2022.013]

5 **Burmeister CA**, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, Prince S. Cervical cancer therapies: Current challenges and future perspectives. *Tumour Virus Res* 2022; **13**: 200238 [PMID: 35460940 DOI: 10.1016/j.tvr.2022.200238]

6 **Tekalign T**, Teshome M. Prevalence and determinants of late-stage presentation among cervical cancer patients, a systematic review and meta-analysis. *PLoS One* 2022; **17**: e0267571 [PMID: 35476851 DOI: 10.1371/journal.pone.0267571]

7 **Mwaka AD**, Garimoi CO, Were EM, Roland M, Wabinga H, Lyratzopoulos G. Social, demographic and healthcare factors associated with stage at diagnosis of cervical cancer: cross-sectional study in a tertiary hospital in Northern Uganda. *BMJ Open* 2016; **6**: e007690 [PMID: 26801459 DOI: 10.1136/bmjopen-2015-007690]

8 **Wang L**, Jia J, Lin L, Guo J, Ye X, Zheng X, Chen Y. Predictive value of hematological markers of systemic inflammation for managing cervical cancer. *Oncotarget* 2017; **8**: 44824-44832 [PMID: 28148894 DOI: 10.18632/oncotarget.14827]

9 **Madeddu C**, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Front Physiol* 2018; **9**: 1294 [PMID: 30294279 DOI: 10.3389/fphys.2018.01294]

10 **Braun A**, Anders HJ, Gudermann T, Mammadova-Bach E. Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. *Front Oncol* 2021; **11**: 665534 [PMID: 34322381 DOI: 10.3389/fonc.2021.665534]

11 **Zhao H**, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduct Target Ther* 2021; **6**: 263 [PMID: 34248142 DOI: 10.1038/s41392-021-00658-5]

12 **Coussens LM**, Werb Z. Inflammation and cancer. *Nature* 2002; **420**: 860-867 [PMID: 12490959 DOI: 10.1038/nature01322]

13 **Xu L**, Song J. Elevated neutrophil-lymphocyte ratio can be a biomarker for predicting the development of cervical intraepithelial neoplasia. *Medicine (Baltimore)* 2021; **100**: e26335 [PMID: 34260524 DOI: 10.1097/MD.0000000000026335]

14 **Ittiamornlert P**, Ruengkhachorn I. Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy. *BMC Cancer* 2019; **19**: 51 [PMID: 30630439 DOI: 10.1186/s12885-019-5269-1]

15 **Zhu M**, Feng M, He F, Han B, Ma K, Zeng X, Liu Z, Liu X, Li J, Cao H, Liang Y, Jia C, Zhang L. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer. *Clin Chim Acta* 2018; **483**: 296-302 [PMID: 29758203 DOI: 10.1016/j.cca.2018.05.025]

16 **Guo W**, Cai S, Zhang F, Shao F, Zhang G, Zhou Y, Zhao L, Tan F, Gao S, He J. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. *Thorac Cancer* 2019; **10**: 761-768 [PMID: 30734516 DOI: 10.1111/1759-7714.12995]

17 **Pacheco-Barcia V**, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, Bouganim N, Guo K, Rogado J, Martin E, Alcindor T, Colomer R. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. *Pancreatology* 2020; **20**: 254-264 [PMID: 31866391 DOI: 10.1016/j.pan.2019.12.010]

18 **Wang L**, Zhou Y, Xia S, Lu L, Dai T, Li A, Chen Y, Gao E. Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients. *Cancer Biomark* 2020; **28**: 537-547 [PMID: 32568185 DOI: 10.3233/CBM-201682]

19 **Chao B**, Ju X, Zhang L, Xu X, Zhao Y. A Novel Prognostic Marker Systemic Inflammation Response Index (SIRI) for Operable Cervical Cancer Patients. *Front Oncol* 2020; **10**: 766 [PMID: 32477958 DOI: 10.3389/fonc.2020.00766]

20 **Bruno M**, Bizzarri N, Teodorico E, Certelli C, Gallotta V, Pedone Anchora L, Fagotti A, Fanfani F, Scambia G, Ferrandina G. The potential role of systemic inflammatory markers in predicting recurrence in early-stage cervical cancer. *Eur J Surg Oncol* 2024; **50**: 107311 [PMID: 38056022 DOI: 10.1016/j.ejso.2023.107311]

21 **Bhatla N**, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. *Int J Gynaecol Obstet* 2018; **143** Suppl 2: 22-36 [PMID: 30306584 DOI: 10.1002/ijgo.12611]

22 **Arbyn M**, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Health* 2020; **8**: e191-e203 [PMID: 31812369 DOI: 10.1016/S2214-109X(19)30482-6]

23 **Flores YN**, Bishai DM, Shah KV, Lazcano-Ponce E, Lörincz A, Hernández M, Ferris D, Salmerón J. Risk factors for cervical cancer among HPV positive women in Mexico. *Salud Publica Mex* 2008; **50**: 49-58 [PMID: 18297182 DOI: 10.1590/s0036-36342008000100011]

24 **Castle PE**, Walker JL, Schiffman M, Wheeler CM. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. *Int J Cancer* 2005; **117**: 1007-1012 [PMID: 15986443 DOI: 10.1002/ijc.21279]

25 **Deacon JM**, Evans CD, Yule R, Desai M, Binns W, Taylor C, Peto J. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. *Br J Cancer* 2000; **83**: 1565-1572 [PMID: 11076670 DOI: 10.1054/bjoc.2000.1523]

26 **Hildesheim A**, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodriguez AC, Helgesen K, Alfaro M, Hutchinson M, Balmaceda I, Greenberg M, Schiffman M. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. *Br J Cancer* 2001; **84**: 1219-1226 [PMID: 11336474 DOI: 10.1054/bjoc.2001.1779]

27 **Kunos CA**, Fabian D, Fredericks T, Baldwin L, Dietrich C, Miller RW, Ueland FR. Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer. *Front Oncol* 2023; **13**: 1132135 [PMID: 37483504 DOI: 10.3389/fonc.2023.1132135]

28 **Wang X**, Xu J, Zhang H, Qu P. The effect of albumin and hemoglobin levels on the prognosis of early-stage cervical cancer: a prospective, single-center-based cohort study. *BMC Womens Health* 2023; **23**: 553 [PMID: 37875880 DOI: 10.1186/s12905-023-02713-5]

29 **Madu AJ**, Ughasoro MD. Anaemia of Chronic Disease: An In-Depth Review. *Med Princ Pract* 2017; **26**: 1-9 [PMID: 27756061 DOI:

10.1159/000452104]

30   **Weiss G**, Ganz T, Goodnough LT. Anemia of inflammation. *Blood* 2019; **133**: 40-50 [PMID: 30401705 DOI: 10.1182/blood-2018-06-856500]

31   **Qing L**, Xiang T, Guofu Z, Weiwei F. Leukemoid reaction in cervical cancer: a case report and review of the literature. *BMC Cancer* 2014; **14**: 670 [PMID: 25223869 DOI: 10.1186/1471-2407-14-670]

32   **Tavares-Murta BM**, Mendonça MA, Duarte NL, da Silva JA, Mutão TS, Garcia CB, Murta EF. Systemic leukocyte alterations are associated with invasive uterine cervical cancer. *Int J Gynecol Cancer* 2010; **20**: 1154-1159 [PMID: 21495217 DOI: 10.1111/igc.0b013e3181ef8deb]

33   **Tas M**, Yavuz A, Ak M, Ozcelik B. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Discriminating Precancerous Pathologies from Cervical Cancer. *J Oncol* 2019; **2019**: 2476082 [PMID: 31558903 DOI: 10.1155/2019/2476082]

34   **Ménétrier-Caux C**, Ray-Coquard I, Blay JY, Caux C. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? *J Immunother Cancer* 2019; **7**: 85 [PMID: 30922400 DOI: 10.1186/s40425-019-0549-5]

35   **de Kleijn S**, Langereis JD, Leentjens J, Kox M, Netea MG, Koenderman L, Ferwerda G, Pickkers P, Hermans PW. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. *PLoS One* 2013; **8**: e72249 [PMID: 24015224 DOI: 10.1371/journal.pone.0072249]

36   **Jain A**, Bobdey S, Sathwara J, Ganesh B, Saoba S, Khan A. Role of monocyte and lymphocyte counts in prognosis of cervical cancer. *Int J Reprod Contracept Obstet Gynecol* 2016 [DOI: 10.18203/2320-1770.ijrcog20162102]

37   **Yin W**, Lv J, Yao Y, Zhao Y, He Z, Wang Q, Cui L, Dai H. Elevations of monocyte and neutrophils, and higher levels of granulocyte colony-stimulating factor in peripheral blood in lung cancer patients. *Thorac Cancer* 2021; **12**: 2680-2690 [PMID: 34498383 DOI: 10.1111/1759-7714.14103]

38   **Sivaprasad S**, Sheela S. Association of Thrombocytosis and its Prognostic Significance in Cervical Cancer. *J Clin Diagn Res* 2023 [DOI: 10.7860/jcdr/2023/60820.17488]

39   **Chaudhary PK**, Kim S, Kim S. An Insight into Recent Advances on Platelet Function in Health and Disease. *Int J Mol Sci* 2022; **23** [PMID: 35682700 DOI: 10.3390/ijms23116022]

40   **Liao K**, Zhang X, Liu J, Teng F, He Y, Cheng J, Yang Q, Zhang W, Xie Y, Guo D, Cao G, Xu Y, Huang B, Wang X. The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy. *MedComm (2020)* 2023; **4**: e350 [PMID: 37719444 DOI: 10.1002/mco2.350]

41   **Prabawa IPY**, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, Budiana ING, Manuaba IBAP. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. *Asian Pac J Cancer Prev* 2019; **20**: 863-868 [PMID: 30912405 DOI: 10.31557/APJCP.2019.20.3.863]

42   **Zou P**, Yang E, Li Z. Neutrophil-to-lymphocyte ratio is an independent predictor for survival outcomes in cervical cancer: a systematic review and meta-analysis. *Sci Rep* 2020; **10**: 21917 [PMID: 33318608 DOI: 10.1038/s41598-020-79071-x]

43   **Ma JY**, Ke LC, Liu Q. The pretreatment platelet-to-lymphocyte ratio predicts clinical outcomes in patients with cervical cancer: A meta-analysis. *Medicine (Baltimore)* 2018; **97**: e12897 [PMID: 30412089 DOI: 10.1097/MD.0000000000012897]

44   **Kast RE**. High Neutrophil-to-Lymphocyte Ratio Facilitates Cancer Growth-Currently Marketed Drugs Tadalafil, Isotretinoin, Colchicine, and Omega-3 to Reduce It: The TICO Regimen. *Cancers (Basel)* 2022; **14** [PMID: 36230888 DOI: 10.3390/cancers14194965]

45   **Lee JW**, Seol KH. Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer. *J Clin Med* 2021; **10** [PMID: 34069592 DOI: 10.3390/jcm10102199]

46   **Huang QT**, Man QQ, Hu J, Yang YL, Zhang YM, Wang W, Zhong M, Yu YH. Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: A systematic review and meta-analysis of observational studies. *Oncotarget* 2017; **8**: 16755-16764 [PMID: 28187430 DOI: 10.18632/oncotarget.15157]

47   **Chen L**, Zhang F, Sheng XG, Zhang SQ. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1-IIa cervical cancer patients who undergo radical surgery. *Onco Targets Ther* 2015; **8**: 1355-1362 [PMID: 26089685 DOI: 10.2147/OTT.S82174]

48   **Gu L**, Li H, Chen L, Ma X, Li X, Gao Y, Zhang Y, Xie Y, Zhang X. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. *Oncotarget* 2016; **7**: 31926-31942 [PMID: 26942464 DOI: 10.18632/oncotarget.7876]

49   **Huang H**, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, Liu L. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. *Sci Rep* 2019; **9**: 3284 [PMID: 30824727 DOI: 10.1038/s41598-019-39150-0]

50   **Ozel I**, Duerig I, Domnich M, Lang S, Pylaeva E, Jablonska J. The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer. *Cancers (Basel)* 2022; **14** [PMID: 35158807 DOI: 10.3390/cancers14030536]

51   **Uribe-Querol E**, Rosales C. Neutrophils in Cancer: Two Sides of the Same Coin. *J Immunol Res* 2015; **2015**: 983698 [PMID: 26819959 DOI: 10.1155/2015/983698]